CAR-T THERAPY FOR
LEUKEMIA
From B-ALL and CLL to AML β approved products, Chinese domestic options, remission rates, and where the field is heading for leukemia patients.
analyticsAt a Glance
- check_circleCAR-T is approved for B-cell ALL (CD19-targeted) and is expanding to AML and T-cell malignancies
- check_circleChina offers NMPA-approved CAR-T at significantly lower cost than the US or UK
- check_circleBispecific CD19/CD22 CAR-T reduces antigen escape relapse β active trials in China and the US
- check_circleCancerFax assists with eligibility review, hospital matching, and travel coordination
Where CAR-T Therapy Began
Leukemia is where CAR-T proved its transformative potential. CD19-directed CAR-T cells produced 70-90% complete remission in relapsed/refractory B-ALL β a disease where prior salvage achieved remission in fewer than 30% of patients.
βThe first paediatric CAR-T patient β Emily Whitehead in 2012 β achieved complete remission and remained disease-free for over a decade.β
Approved CAR-T Products for Leukemia
| Product | Indication | Key Efficacy | Notes |
|---|---|---|---|
| Kymriah (tisa-cel) | r/r B-ALL, age β€25 | CR 81%; MRD-negative 80% | First approved CAR-T (2017) |
| Breyanzi (liso-cel) | r/r B-ALL, adults β₯18 | CR/CRi 63% | Approved 2024 for adult ALL |
| Breyanzi (liso-cel) | r/r CLL/SLL after BTKi + venetoclax | ORR 43%; CR 20% | First CAR-T for CLL (2024) |
Antigen Escape: The Primary Resistance Problem
CD19 loss occurs in 20-30% of patients who relapse after CD19 CAR-T. Strategies to address this include dual-targeting CD19/CD22 constructs and sequential CD22 CAR-T after CD19 failure.
CD22 CAR-T
Produces remission in 70-80% of CD19-negative relapsed ALL patients. Not yet commercially approved.
Dual CD19/CD22 Targeting
Simultaneous targeting reduces escape risk. Chinese academic centres (Beijing, Kunming) are leading this development.
CAR-T for AML: The Unresolved Frontier
AML lacks a single universal surface antigen absent from normal bone marrow. Every AML target (CD33, CD123, CLL-1, FLT3) is also expressed on normal haematopoietic stem cells.
CLL-1/CLEC12A Targeting
Expressed on AML leukemic stem cells; potentially more specific than CD33 or CD123. Chinese trials at 920th Hospital show encouraging Phase I/II data.
CD33 CAR-T + Transplant Rescue
CD33 CAR-T eliminates AML but also normal myeloid cells. Followed by stem cell transplant to rescue from aplasia.
Frequently Asked Questions
CAR-T for Leukemia
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring CAR-T Options for Leukemia?
Upload your reports for a specialist evaluation. We help leukemia patients access approved CAR-T products and AML clinical trials globally.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.